ReviewTranslational andrology and urology2018
Genomic biomarkers in prostate cancer.
Review in Translational andrology and urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Radiomic and Genomic Machine Learning Method Performance for Prostate Cancer Diagnosis: Systematic Literature Review.Journal of medical Internet research · 2021Pooled it
- Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2019Trial
- Evaluating Differential Metabolic Profiles by Prostate Cancer Risk Among Prostate Cancer Patients.Metabolites · 2025Article
- The Role of Genomic Scores in the Management of Prostate Cancer Patients: A Comprehensive Narrative Review.Cancers · 2025Review
- Differentiation of high risk prostate cancer with a facile urinary exosome detection workflow.iScience · 2025Article
- Can we predict pathology without surgery? Weighing the added value of multiparametric MRI and whole prostate radiomics in integrative machine learning models.European radiology · 2024Article
- Prostate cancer biomarkers: from early diagnosis to precision treatment.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Review
- Artificial intelligence applications in prostate cancer.Prostate cancer and prostatic diseases · 2024Review
- Article
- Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials.NPJ digital medicine · 2022Article
- Protein signatures to distinguish aggressive from indolent prostate cancer.The Prostate · 2022Article
- Review
- Correlative analysis between two commercially available post-prostatectomy genomic tests.Prostate cancer and prostatic diseases · 2021Article
- A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance.Nature cancer · 2020Article
- Kallikrein gene family as biomarkers for recurrent prostate cancer.Croatian medical journal · 2020Article
- Article
- The preventative effect of bone marrow-derived mesenchymal stem cell exosomes on urethral stricture in rats.Translational andrology and urology · 2020Article
- RASSF10 is frequently epigenetically inactivated in kidney cancer and its knockout promotes neoplasia in cancer prone mice.Oncogene · 2020Article
- Decipher identifies men with otherwise clinically favorable-intermediate risk disease who may not be good candidates for active surveillance.Prostate cancer and prostatic diseases · 2020Article
- SPINK1 expression is enriched in African American prostate cancer but is not associated with altered immune infiltration or oncologic outcomes post-prostatectomy.Prostate cancer and prostatic diseases · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is the most common non-cutaneous cancer among men in the United States. In the last decade there has been a rapid expansion in the field of biomarker assays for diagnosis, prognosis, and treatment prediction in prostate cancer. The evidence base for these assays is rapidly evolving. With several commercial assays available at each stage of the disease, deciding which genomic assays are appropriate for which patients can be nuanced for physicians. In an effort to help guide these decisions in clinical practice, we aim to give an update on the current status of the biomarker field of prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.